Merck Millipore Announces Partnership with NIH Consortium
News Oct 16, 2012
Merck Millipore has announced that Merck Millipore has entered into an agreement with an academic consortium funded by the NIH, to distribute more than 140 peer-validated neuroscience-specific monoclonal antibodies through its worldwide network.
This set of antibodies has been specifically requested by academic researchers for key targets in neuroscience research.
The antibodies have been submitted and vetted through a formal process, led by academicians, and have been determined to be valuable and worthy of development in light of today's neuroscience research priorities.
These key targets in neurodevelopment, metabolism, oxidative stress, synaptic function, neurodegeneration and disease have been tested in multiple species, including genetic knockout mice.
In addition, the antibodies have been independently peer-reviewed and research validated prior to being made available through Merck Millipore.
"Merck Millipore's objective is to help our customers advance the study of neuroscience," notes John Sweeney, Executive Vice President, Merck Millipore Bioscience Division.
Sweeney continued, "We are excited about this partnership with the NIH consortium, one of the largest sources of medical research funding in the world. This partnership will enable us to provide access to this novel range of neuroscience antibodies in addition to others, allowing us to provide cutting edge tools for researchers focused on metabolism, oxidative stress, synaptic function, neurodegeneration and more."
Merck Millipore is currently one of the top antibody manufacturers worldwide, with the majority of antibodies licensed and manufactured in California.
A significant number of Merck Millipore's antibody portfolio and technical expertise includes antibodies and research staff from Chemicon®, Upstate®, Linco® and Calbiochem®, which were acquired by the company over the past several years.
With its primary focus on quality and stringent validation, Merck Millipore's antibodies are backed by its commitment to quality and a unique performance guarantee.
In addition to developing and testing a wide range of antibodies, Merck Millipore has research and development teams dedicated to expanding its significant portfolio of immunotechnologies including its Multiplex, Elisas, and other cell-based assays, as well as novel flow cytometry, guava easycyte®, Amnis® and Muse® products for cell analysis and imaging.
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE